STARR CHRISTOPHER M sold $659K of MNPR
STARR CHRISTOPHER M sold 8,400 shares of Monopar Therapeutics (MNPR) at an average of $78.50 ($78.09–$79.67, $0.66M total) across 3 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction reduces insider ownership and may be interpreted as a lack of confidence, prompting short‑term price pressure.
Market read
Primary insider sale news for a micro‑cap biotech; modest trading relevance.
What to watch
Potential upcoming clinical data releases that may offset the negative signal.
Background
Form 4 filings are primary disclosures of insider transactions. This filing reports a director’s sale under a pre‑arranged 10b5‑1 plan.
Ticker impact
Director Christopher Starr sold 8,400 shares for $659K via a 10b5‑1 plan, reducing his stake to 5,173 shares.
likely pressure as investors price in the insider sell
A director’s open‑market sale of $0.66 M is material for a micro‑cap biotech and often triggers short‑term selling pressure.
Market effects
Minimal; the sale does not affect the broader biotech sector.
None; impact confined to the company.
Low; no broader market relevance.
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals.
Key entities
- companyMonopar Therapeutics
Biotech firm (ticker MNPR) whose director sold shares.
- personChristopher Starr
Director of Monopar Therapeutics who executed the sale.
